Teva Pharmaceutical Names Board Member to Be New CEO

Following the departure of then-Teva Pharmaceutical (NYSE: TEVA  ) CEO Jeremy Levin on Oct. 30, 2013, then-CFO Eyal Desheh was promoted to acting president and CEO until a successor could be found. Today, Teva announced that current board member Erez Vigodman would assume the president and CEO role on a permanent basis beginning Feb. 11.

Desheh will return to his prior position as group executive vice president and CFO, Teva said.

Vigodman, 54, is currently CEO of agrochemical provider Makhteshim Agan Industries (MAI), a position he's held since January 2010. According to Teva's press release, Vigodman intends to step down as CEO of MAI on Feb. 6.

In its statement, Teva Chairman of the Board Phillip Frost commented: "As a member of the Teva Board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders."

Israel-based Teva hopes to bring some stability to the leadership position with the hiring of Vigodman, following what some industry pundits considered to be a tumultuous time while Levin was CEO. Disagreements on implementing an agreed-upon restructuring initiative was the impetus, according to analysts and pharma insiders, for Levin's departure from Teva last October.

Teva has long been a source of pride in Israel, and the company noted that its next CEO is Israeli. But the drugmaker's image has been tarnished by plans for mass layoffs, including hundreds of jobs in Israel, where the company has enjoyed years of tax breaks and other incentives.

The layoffs are part of a restructuring aimed at slimming Teva's business and making it more efficient.

-- Material from The Associated Press was used in this report.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2789351, ~/Articles/ArticleHandler.aspx, 9/4/2015 8:42:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Tim Brugger

Tim has been writing professionally for several years after spending 18 years (Whew! Was it that long?)in both the retail and institutional side of the financial services industry. Tim resides in Portland, Oregon with his three children and the family dog.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 4:01 PM
TEVA $64.12 Down +0.00 +0.00%
Teva Pharmaceutica… CAPS Rating: *****